Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ambrx Biopharma stock

Learn how to easily invest in Ambrx Biopharma stock.

Ambrx Biopharma Inc.
+$0.42 (+2.29%)

Ambrx Biopharma Inc. is a biotechnology business based in the US. Ambrx Biopharma shares (AMAM) are listed on the NYSE and all prices are listed in US Dollars. Ambrx Biopharma employs 70 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ambrx Biopharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMAM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ambrx Biopharma stock price (NYSE: AMAM)

Use our graph to track the performance of AMAM stocks over time.

Ambrx Biopharma shares at a glance

Information last updated 2021-07-28.
52-week range$14.94 - $22.87
50-day moving average $19.50
200-day moving average $19.50
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Ambrx Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ambrx Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ambrx Biopharma financials

Revenue TTM $13.7 million
Gross profit TTM $13.7 million
Return on assets TTM -8.38%
Return on equity TTM -23.65%
Profit margin -121.01%
Book value N/A
Market capitalisation $828.4 million

TTM: trailing 12 months

Shorting Ambrx Biopharma shares

There are currently 15,825 Ambrx Biopharma shares held short by investors – that's known as Ambrx Biopharma's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting Ambrx Biopharma shares can be evaluated.

Ambrx Biopharma's "short interest ratio" (SIR)

Ambrx Biopharma's "short interest ratio" (SIR) is the quantity of Ambrx Biopharma shares currently shorted divided by the average quantity of Ambrx Biopharma shares traded daily (recently around 131875). Ambrx Biopharma's SIR currently stands at 0.12. In other words for every 100,000 Ambrx Biopharma shares traded daily on the market, roughly 120 shares are currently held short.

To gain some more context, you can compare Ambrx Biopharma's short interest ratio against those of similar companies.

However Ambrx Biopharma's short interest can also be evaluated against the total number of Ambrx Biopharma shares, or, against the total number of tradable Ambrx Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ambrx Biopharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Ambrx Biopharma shares in existence, roughly 0 shares are currently held short) or 1.3205% of the tradable shares (for every 100,000 tradable Ambrx Biopharma shares, roughly 1321 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ambrx Biopharma.

Find out more about how you can short Ambrx Biopharma stock.

Ambrx Biopharma share dividends

We're not expecting Ambrx Biopharma to pay a dividend over the next 12 months.

Ambrx Biopharma overview

Ambrx Biopharma Inc. , a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc. , Sino Biopharmaceutical Co.

Stocks similar to Ambrx Biopharma

Frequently asked questions

What percentage of Ambrx Biopharma is owned by institutions?
Currently 8.806% of Ambrx Biopharma shares are held by institutions.
How many people work for Ambrx Biopharma?
Latest data suggests 70 work at Ambrx Biopharma.
When does the fiscal year end for Ambrx Biopharma?
Ambrx Biopharma's fiscal year ends in December.
Where is Ambrx Biopharma based?
Ambrx Biopharma's address is: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site